Susana Maria Campos, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endometrial Neoplasms | 14 | 2023 | 1357 | 1.770 |
Why?
|
Ovarian Neoplasms | 28 | 2023 | 4878 | 1.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2023 | 11713 | 1.320 |
Why?
|
Peritoneal Neoplasms | 14 | 2024 | 707 | 1.240 |
Why?
|
Fallopian Tube Neoplasms | 10 | 2016 | 328 | 1.150 |
Why?
|
Genital Neoplasms, Female | 8 | 2024 | 533 | 1.130 |
Why?
|
Neoplasm Recurrence, Local | 27 | 2022 | 9278 | 0.950 |
Why?
|
Uterine Neoplasms | 9 | 2023 | 1439 | 0.840 |
Why?
|
Mixed Tumor, Mullerian | 5 | 2014 | 55 | 0.690 |
Why?
|
Uterine Cervical Neoplasms | 14 | 2023 | 2003 | 0.670 |
Why?
|
Carcinosarcoma | 3 | 2023 | 104 | 0.670 |
Why?
|
DNA Polymerase II | 1 | 2019 | 104 | 0.630 |
Why?
|
Carboplatin | 11 | 2022 | 789 | 0.600 |
Why?
|
Aromatase Inhibitors | 3 | 2009 | 511 | 0.570 |
Why?
|
Carcinoma, Endometrioid | 2 | 2023 | 276 | 0.560 |
Why?
|
Vulvar Neoplasms | 3 | 2024 | 263 | 0.470 |
Why?
|
Paclitaxel | 9 | 2022 | 1737 | 0.460 |
Why?
|
Doxorubicin | 10 | 2020 | 2208 | 0.430 |
Why?
|
Neoplasm Staging | 25 | 2020 | 11152 | 0.420 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 666 | 0.420 |
Why?
|
Antimitotic Agents | 1 | 2012 | 29 | 0.400 |
Why?
|
Tubulin Modulators | 1 | 2012 | 107 | 0.390 |
Why?
|
Hematinics | 2 | 2005 | 281 | 0.370 |
Why?
|
Breast Neoplasms | 12 | 2022 | 21029 | 0.350 |
Why?
|
Nitriles | 4 | 2009 | 956 | 0.340 |
Why?
|
Androstadienes | 2 | 2009 | 348 | 0.330 |
Why?
|
Erythropoietin | 2 | 2005 | 720 | 0.330 |
Why?
|
Triazoles | 4 | 2009 | 904 | 0.330 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1424 | 0.320 |
Why?
|
Antineoplastic Agents | 11 | 2021 | 13627 | 0.320 |
Why?
|
Teratoma | 1 | 2011 | 403 | 0.310 |
Why?
|
Angiogenesis Inhibitors | 3 | 2014 | 2049 | 0.290 |
Why?
|
Adenocarcinoma | 6 | 2024 | 6316 | 0.280 |
Why?
|
Glioblastoma | 1 | 2021 | 3482 | 0.270 |
Why?
|
Pyrroles | 1 | 2012 | 1137 | 0.260 |
Why?
|
Female | 85 | 2024 | 391246 | 0.260 |
Why?
|
Needs Assessment | 1 | 2012 | 1139 | 0.260 |
Why?
|
Disease-Free Survival | 9 | 2020 | 6831 | 0.240 |
Why?
|
Anemia | 2 | 2005 | 1511 | 0.230 |
Why?
|
Quinazolines | 3 | 2022 | 1363 | 0.230 |
Why?
|
Desensitization, Immunologic | 3 | 2016 | 534 | 0.230 |
Why?
|
Indoles | 1 | 2012 | 1829 | 0.230 |
Why?
|
Sulfonamides | 1 | 2014 | 1977 | 0.230 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2021 | 2418 | 0.230 |
Why?
|
Drug Administration Schedule | 12 | 2020 | 4899 | 0.220 |
Why?
|
Neoplasms | 7 | 2022 | 22075 | 0.220 |
Why?
|
Estrogen Receptor Modulators | 1 | 2003 | 58 | 0.210 |
Why?
|
Enzyme Inhibitors | 2 | 2004 | 3725 | 0.210 |
Why?
|
Morpholines | 1 | 2005 | 583 | 0.200 |
Why?
|
Humans | 95 | 2024 | 760613 | 0.200 |
Why?
|
Hemoglobins | 2 | 2005 | 1521 | 0.200 |
Why?
|
Sexual Behavior | 1 | 2012 | 2086 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 4 | 2020 | 5640 | 0.200 |
Why?
|
Pyrazoles | 3 | 2021 | 1999 | 0.200 |
Why?
|
Survivors | 2 | 2012 | 2375 | 0.200 |
Why?
|
Pyrimidines | 1 | 2014 | 3016 | 0.190 |
Why?
|
Endodermal Sinus Tumor | 1 | 2022 | 53 | 0.190 |
Why?
|
Middle Aged | 49 | 2024 | 220359 | 0.190 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2023 | 217 | 0.190 |
Why?
|
Telemedicine | 3 | 2024 | 3018 | 0.190 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2005 | 675 | 0.190 |
Why?
|
Aged | 46 | 2024 | 169143 | 0.190 |
Why?
|
Pyrimidinones | 2 | 2021 | 384 | 0.190 |
Why?
|
Cyclodextrins | 1 | 2021 | 65 | 0.190 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5349 | 0.190 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2017 | 4024 | 0.190 |
Why?
|
Feasibility Studies | 4 | 2024 | 5201 | 0.180 |
Why?
|
Postmenopause | 3 | 2009 | 2509 | 0.180 |
Why?
|
Isoindoles | 1 | 2020 | 36 | 0.180 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2005 | 1529 | 0.180 |
Why?
|
Anthracyclines | 1 | 2003 | 283 | 0.180 |
Why?
|
Drug Hypersensitivity | 3 | 2016 | 916 | 0.180 |
Why?
|
Receptor, erbB-2 | 7 | 2022 | 2554 | 0.180 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 429 | 0.170 |
Why?
|
Cystadenocarcinoma, Serous | 3 | 2021 | 479 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2020 | 5251 | 0.160 |
Why?
|
Medical Oncology | 5 | 2019 | 2313 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2012 | 3530 | 0.150 |
Why?
|
Maximum Tolerated Dose | 4 | 2020 | 877 | 0.150 |
Why?
|
Sarcoma | 3 | 2021 | 1786 | 0.150 |
Why?
|
Antibodies, Monoclonal | 8 | 2022 | 9185 | 0.150 |
Why?
|
Omentum | 1 | 2019 | 169 | 0.150 |
Why?
|
Treatment Outcome | 23 | 2022 | 64981 | 0.150 |
Why?
|
Vinblastine | 4 | 2020 | 487 | 0.150 |
Why?
|
Camptothecin | 1 | 2021 | 590 | 0.150 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2013 | 487 | 0.140 |
Why?
|
Hospice Care | 1 | 2023 | 692 | 0.140 |
Why?
|
Deoxycytidine | 5 | 2015 | 872 | 0.130 |
Why?
|
Neoplasm Proteins | 1 | 2008 | 3612 | 0.130 |
Why?
|
Papillomavirus Infections | 2 | 2019 | 1607 | 0.130 |
Why?
|
Pilot Projects | 6 | 2024 | 8556 | 0.130 |
Why?
|
Cell Cycle Proteins | 2 | 2021 | 3448 | 0.130 |
Why?
|
Adult | 38 | 2024 | 220007 | 0.130 |
Why?
|
Caregivers | 2 | 2024 | 2224 | 0.120 |
Why?
|
Benzamides | 1 | 2020 | 1369 | 0.120 |
Why?
|
Sirolimus | 1 | 2022 | 1547 | 0.120 |
Why?
|
Rectal Neoplasms | 3 | 2008 | 1152 | 0.120 |
Why?
|
Epoetin Alfa | 2 | 2005 | 79 | 0.120 |
Why?
|
Ligands | 3 | 2022 | 3276 | 0.110 |
Why?
|
Organoplatinum Compounds | 2 | 2013 | 410 | 0.110 |
Why?
|
Hernia, Ventral | 1 | 1997 | 214 | 0.110 |
Why?
|
Injections, Intraperitoneal | 2 | 2012 | 412 | 0.110 |
Why?
|
Piperidines | 2 | 2020 | 1650 | 0.110 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2058 | 0.100 |
Why?
|
Cisplatin | 3 | 2020 | 1643 | 0.100 |
Why?
|
Neoadjuvant Therapy | 4 | 2013 | 2821 | 0.100 |
Why?
|
Guidelines as Topic | 3 | 2020 | 1392 | 0.100 |
Why?
|
Taxoids | 1 | 2015 | 669 | 0.100 |
Why?
|
Indazoles | 1 | 2014 | 302 | 0.100 |
Why?
|
Infusions, Intravenous | 5 | 2020 | 2235 | 0.100 |
Why?
|
Terminal Care | 1 | 2023 | 1758 | 0.100 |
Why?
|
Quality of Life | 5 | 2024 | 13308 | 0.090 |
Why?
|
Uterine Cervical Dysplasia | 2 | 2004 | 384 | 0.090 |
Why?
|
Recombinant Proteins | 3 | 2005 | 6538 | 0.090 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2014 | 517 | 0.090 |
Why?
|
Combined Modality Therapy | 8 | 2013 | 8552 | 0.090 |
Why?
|
Phthalazines | 2 | 2022 | 382 | 0.080 |
Why?
|
Aged, 80 and over | 11 | 2021 | 58980 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3617 | 0.080 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2021 | 423 | 0.080 |
Why?
|
Liposomes | 2 | 2003 | 777 | 0.080 |
Why?
|
Prognosis | 9 | 2016 | 29661 | 0.080 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2006 | 628 | 0.070 |
Why?
|
Genes, erbB-1 | 1 | 2008 | 160 | 0.070 |
Why?
|
Survival Rate | 6 | 2017 | 12810 | 0.070 |
Why?
|
Disease Progression | 6 | 2022 | 13505 | 0.070 |
Why?
|
Receptor, erbB-3 | 1 | 2008 | 143 | 0.070 |
Why?
|
Dioxoles | 1 | 2007 | 95 | 0.070 |
Why?
|
Tetrahydroisoquinolines | 1 | 2007 | 81 | 0.070 |
Why?
|
Topotecan | 5 | 2006 | 132 | 0.070 |
Why?
|
Retrospective Studies | 8 | 2022 | 80345 | 0.070 |
Why?
|
Brachytherapy | 3 | 2019 | 1238 | 0.070 |
Why?
|
Cohort Studies | 5 | 2019 | 41337 | 0.070 |
Why?
|
Receptors, Estrogen | 3 | 2022 | 2210 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 10826 | 0.070 |
Why?
|
Oncogene Proteins v-erbB | 1 | 2005 | 17 | 0.070 |
Why?
|
Immunotherapy | 2 | 2020 | 4642 | 0.060 |
Why?
|
Administration, Oral | 3 | 2012 | 4035 | 0.060 |
Why?
|
Filgrastim | 1 | 2005 | 132 | 0.060 |
Why?
|
Clinical Trials as Topic | 4 | 2013 | 8055 | 0.060 |
Why?
|
Megestrol Acetate | 1 | 2004 | 18 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5787 | 0.060 |
Why?
|
Hysterectomy | 3 | 2019 | 904 | 0.060 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 253 | 0.060 |
Why?
|
Paget Disease, Extramammary | 1 | 2024 | 51 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2010 | 1268 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3527 | 0.050 |
Why?
|
Daunorubicin | 1 | 2003 | 155 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Radiography | 2 | 2011 | 6965 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 84 | 0.050 |
Why?
|
Adenovirus E1B Proteins | 1 | 2002 | 14 | 0.050 |
Why?
|
Pregnancy Complications, Neoplastic | 3 | 2010 | 255 | 0.050 |
Why?
|
Risk | 1 | 2014 | 9632 | 0.050 |
Why?
|
Interdisciplinary Communication | 1 | 2007 | 934 | 0.050 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2008 | 1652 | 0.050 |
Why?
|
Interprofessional Relations | 1 | 2007 | 989 | 0.050 |
Why?
|
Progestins | 1 | 2003 | 302 | 0.050 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2022 | 430 | 0.040 |
Why?
|
Skin Tests | 2 | 2015 | 637 | 0.040 |
Why?
|
Boston | 2 | 2010 | 9278 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 630 | 0.040 |
Why?
|
Nausea | 1 | 2003 | 678 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 1 | 2012 | 4496 | 0.040 |
Why?
|
Time Factors | 4 | 2010 | 40139 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 59 | 0.040 |
Why?
|
Tamoxifen | 1 | 2004 | 963 | 0.040 |
Why?
|
Bleomycin | 1 | 2020 | 495 | 0.040 |
Why?
|
Survival Analysis | 3 | 2009 | 10185 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1189 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2005 | 1328 | 0.040 |
Why?
|
Mass Screening | 3 | 2019 | 5422 | 0.040 |
Why?
|
Alopecia | 1 | 2003 | 414 | 0.040 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2020 | 397 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6544 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12159 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 256 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15840 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 3484 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2005 | 1046 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7475 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 765 | 0.040 |
Why?
|
Chromosome Deletion | 1 | 2022 | 1387 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 2221 | 0.040 |
Why?
|
Cell Differentiation | 1 | 2014 | 11481 | 0.030 |
Why?
|
Aminopterin | 1 | 2016 | 15 | 0.030 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2003 | 1153 | 0.030 |
Why?
|
Advance Care Planning | 1 | 2024 | 697 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 951 | 0.030 |
Why?
|
Scalp | 1 | 1999 | 389 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1544 | 0.030 |
Why?
|
Early Detection of Cancer | 1 | 2010 | 3202 | 0.030 |
Why?
|
Decision Trees | 2 | 2008 | 506 | 0.030 |
Why?
|
Colposcopy | 2 | 2008 | 150 | 0.030 |
Why?
|
Colonic Diseases | 1 | 1997 | 200 | 0.030 |
Why?
|
Giant Cell Arteritis | 1 | 1999 | 296 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3618 | 0.030 |
Why?
|
Cervix Uteri | 1 | 2019 | 582 | 0.030 |
Why?
|
Brain | 1 | 2021 | 26951 | 0.030 |
Why?
|
Mutation | 1 | 2019 | 29957 | 0.030 |
Why?
|
Gene Deletion | 1 | 2022 | 2668 | 0.030 |
Why?
|
Neoplasm Metastasis | 3 | 2013 | 4902 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 792 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10343 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2864 | 0.030 |
Why?
|
Heart Diseases | 2 | 2003 | 2809 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2009 | 4319 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1117 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 1999 | 1431 | 0.030 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 482 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2016 | 2262 | 0.030 |
Why?
|
Remission Induction | 1 | 2017 | 2392 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1791 | 0.020 |
Why?
|
Motivation | 1 | 2021 | 1993 | 0.020 |
Why?
|
Pregnancy | 4 | 2019 | 29746 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2448 | 0.020 |
Why?
|
Risk Factors | 3 | 2017 | 74333 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2013 | 424 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3164 | 0.020 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2016 | 800 | 0.020 |
Why?
|
Recurrence | 2 | 2012 | 8483 | 0.020 |
Why?
|
Palliative Care | 1 | 2023 | 3607 | 0.020 |
Why?
|
Myometrium | 1 | 2009 | 176 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2008 | 66 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2009 | 8985 | 0.020 |
Why?
|
Guanine | 1 | 2008 | 278 | 0.020 |
Why?
|
Glutamates | 1 | 2008 | 391 | 0.020 |
Why?
|
Population Surveillance | 1 | 2017 | 2608 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3905 | 0.020 |
Why?
|
Endometrium | 1 | 2009 | 403 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2222 | 0.020 |
Why?
|
Male | 7 | 2020 | 359718 | 0.020 |
Why?
|
Young Adult | 1 | 2012 | 58748 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6771 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2024 | 5799 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2009 | 13262 | 0.010 |
Why?
|
Adolescent | 2 | 2009 | 87809 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 1660 | 0.010 |
Why?
|
Etoposide | 1 | 2005 | 630 | 0.010 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2003 | 56 | 0.010 |
Why?
|
Hormone Replacement Therapy | 1 | 2009 | 755 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2010 | 1784 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3258 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2008 | 1440 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2009 | 2897 | 0.010 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2002 | 105 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2005 | 629 | 0.010 |
Why?
|
Disease Management | 1 | 2013 | 2514 | 0.010 |
Why?
|
Vaginal Smears | 1 | 2004 | 495 | 0.010 |
Why?
|
Risk Assessment | 2 | 2015 | 24102 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13312 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2005 | 861 | 0.010 |
Why?
|
Perioperative Care | 1 | 2008 | 1037 | 0.010 |
Why?
|
Plasmids | 1 | 2005 | 2275 | 0.010 |
Why?
|
Algorithms | 3 | 2004 | 13982 | 0.010 |
Why?
|
Receptors, Progesterone | 1 | 2003 | 1130 | 0.010 |
Why?
|
Adenoviridae | 1 | 2002 | 1084 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2005 | 1998 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 3696 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23374 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 2852 | 0.010 |
Why?
|
ROC Curve | 1 | 2003 | 3568 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7805 | 0.010 |
Why?
|
Necrosis | 1 | 1999 | 1612 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39262 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2007 | 3598 | 0.010 |
Why?
|
Virus Replication | 1 | 2002 | 2432 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 1997 | 20509 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2002 | 2924 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2002 | 3142 | 0.010 |
Why?
|
United States | 1 | 2019 | 72448 | 0.010 |
Why?
|
Pyridines | 1 | 2002 | 2879 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36286 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2001 | 1951 | 0.010 |
Why?
|
Prospective Studies | 1 | 2012 | 54306 | 0.000 |
Why?
|
Predictive Value of Tests | 1 | 2003 | 15286 | 0.000 |
Why?
|